Cannabis sativa is a plant that has been used for many purposes. Certain parts of the plant have been found to have medicinal properties, such as Delta-8 THC and the Data Acceleration Plan for CBD. Under federal law, CBD derived from cannabis plants with more than 0.3% THC is classified as a Schedule I drug. This means that if the cannabis plant has more than 0.3% THC, it is considered to be a Schedule I drug by the Drug Enforcement Administration (DEA).
The DEA categorizes drugs based on their potential for abuse or dependence, as well as their accepted medical use. Schedule I drugs are those that have a high potential for abuse and no accepted medical use. This means that CBD derived from cannabis plants with more than 0.3% THC is considered to be a Schedule I drug by the DEA. CBD derived from hemp plants, on the other hand, is not considered to be a Schedule I drug.
Hemp plants are cannabis plants that contain less than 0.3% THC, and therefore are not subject to the same restrictions as cannabis plants with more than 0.3% THC. CBD derived from hemp plants is legal in most states and can be used for medicinal purposes without fear of legal repercussions.
